World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
42690
World Ranking
16878
National Ranking
45

Nir Peled publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nir Peled sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 409 publications — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nir Peled D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nir Peled sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nir Peled is affiliated with Ben-Gurion University of the Negev in Israel and has an extensive publication record primarily in the field of Medicine with a focus on Pulmonary and Respiratory Medicine and Oncology. Their work spans various subfields including Molecular Biology, Cancer Research, and Radiology, Nuclear Medicine and Imaging.

The main topics addressed in their research include:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Radiomics and Machine Learning in Medical Imaging

Nir Peled's frequent publication venues encompass several leading journals in oncology and thoracic medicine:

  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Frontiers in Oncology
  • Cancer Research

Collaborations have been an essential aspect of their career, with repeated co-authorships involving researchers such as Waleed Kian, Laila C. Roisman, Elizabeth Dudnik, Alona Zer, and Maximilian J. Hochmair.

Recent notable papers include:

  • "Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer", 2020, Journal of Clinical Oncology
  • "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%", 2021, Journal of Clinical Oncology
  • "Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer", 2020, New England Journal of Medicine
  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer", 2021, Journal of Thoracic Oncology
  • "Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study", 2023, Journal of Clinical Oncology

Best Publications

  • Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Volatile organic compounds of lung cancer and possible biochemical pathways.

    Meggie Hakim;Yoav Y. Broza;Orna Barash;Nir Peled

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

  • Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules

    Morad K. Nakhleh;Haitham Amal;Raneen Jeries;Yoav Y. Broza

  • Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Luis M. Seijo;Nir Peled;Daniel Ajona;Mattia Boeri

  • Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors

    E. Izumchenko;K. Paz;D. Ciznadija;I. Sloma

  • Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

    Alexa B. Schrock;Garrett M. Frampton;James Suh;Zachary R. Chalmers

  • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

    Julie R Brahmer;Delvys Rodríguez-Abreu;Andrew G Robinson;Rina Hui

  • Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry

    Oliver Gautschi;Julie Milia;Thomas Filleron;Juergen Wolf

  • Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment.

    Nir Peled;Edward G Abinader;Giora Pillar;Dawood Sharif

  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

    D. Rodríguez-Abreu;S.F. Powell;M.J. Hochmair;S. Gadgeel

  • ESR/ERS white paper on lung cancer screening

    Hans-Ulrich Kauczor;Lorenzo Bonomo;Mina Gaga;Kristiaan Nackaerts

  • Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Anne Marie C. Dingemans;Anne Marie C. Dingemans;Lizza E.L. Hendriks;Thierry Berghmans;Antonin Levy

Frequent Co-Authors

Martin Reck
Martin Reck LungenClinic Grosshansdorf
Hossam Haick
Hossam Haick Technion – Israel Institute of Technology
Siraj M. Ali
Siraj M. Ali Foundation Medicine
Fred R. Hirsch
Fred R. Hirsch Mount Sinai Hospital
Mary O'Brien
Mary O'Brien Royal Marsden NHS Foundation Trust
Paul A. Bunn
Paul A. Bunn University of Colorado Boulder
Garrett M. Frampton
Garrett M. Frampton Foundation Medicine
Peretz Lavie
Peretz Lavie Technion – Israel Institute of Technology
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up a variety of online degree and career opportunities beyond the traditional MD path. Many healthcare professionals seek flexible, affordable ways to advance their education and expertise while balancing work and life commitments.

For nurses aiming to reach the highest levels of practice, cheap online dnp programs offer cost-effective options to earn a Doctor of Nursing Practice degree. Pharmacists can also benefit from flexible learning through accredited pharm d online programs, which prepare graduates for advanced roles in pharmacy and patient care.

The healthcare industry relies on skilled professionals in data management and administration. Those interested can choose a him degree online to pursue careers in managing health records, privacy, and compliance. Additionally, there is strong demand for experts in billing and insurance processes, with a medical coding certification serving as a gateway to roles in medical billing and coding.

These online degree pathways provide practical routes to fulfilling healthcare careers, making advanced education more accessible and affordable than ever.

Best Scientists Citing Nir Peled

Trending Scientists